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Abstract
A new detailed mathematical model for dynamics of immune response to hepatitis B is proposed,
which takes into account contributions from innate and adaptive immune responses, as well as
cytokines. Stability analysis of different steady states is performed to identify parameter regions
where the model exhibits clearance of infection, maintenance of a chronic infection, or periodic
oscillations. Effects of nucleoside analogues and interferon treatments are analysed, and the critical
drug efficiency is determined.
1 Introduction
Hepatitis B is a major viral infectious disease that affects a third of the world population, with 240-350
million people having a chronic infection [1, 2], and over 129 million new infections having occurred
since 2013 [3]. This disease is a significant public health burden, causing 750,000 deaths annually [2],
of which about 300,000 can be attributed to liver cirrhosis and hepatocellular carcinoma [4]. Whilst
the prevalence of hepatitis B is relatively low (below 1%) in Western Europe and North America, it
remains significant in south-east Asia and sub-Saharan Africa, where 5-10% of the adult population
are chronically infected [2].
The disease is caused by the hepatitis B virus (HBV), which is a hepatotropic noncytopathic
DNA virus of the Hepadnaviridae family [5]. There are two main routes of transmission of the HBV
virus. One is a vertical (perinatal) transmission from an infected mother to a child, resulting in
subsequent infection, which in 90% of cases becomes chronic [6, 7]. The other possibility is a horizontal
transmission between adults primarily through sexual contacts, intravenous drug use or poor sanitary
habits. This type of transmission usually results in recovery, with only 5-10% of adults developing
chronic infections [6, 7]. Multiple branches of the immune system are involved in mounting the
response during different phases of the HBV infection. In many viral infections of humans, such as
HIV, LCMV, Epstein-Barr, the main contribution to the immune response during the early stages of
infection comes from the innate immune response, i.e. natural killer (NK) cells and antiviral cytokines,
which aim at reducing the spread of the virus and facilitating the development of an adaptive immune
response. Contrary to this general observation, early stages of HBV infection are characterised by a
delayed viral production and the lack of production of IFN-α/β [8]. Several potential suggestions have
been proposed to explain this, including the possibilities that the initial replication of HBV is very
slow, or that the virus does not immediately reach the liver and remains for a period of time in other
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organs [8, 9], however, the exact mechanism is still largely unknown. Once the exponential phase of
HBV expansions properly starts, it activates the innate response and the cytokines [10], which, in
turn, induces adaptive immune response, with cytotoxic T lymphocytes (CTLs) being responsible for
killing infected cells, and antibodies against HBV surface antigen (HBsAg) neutralizing virus particles
and preventing (re)infection of cells. Interestingly, besides killing HBV-infected hepatocytes, CTLs
are able to induce non-cytolytic “cure” of such cells [11, 10, 12]. An important role in the dynamics
of immune response against HBV is played by cytokines, which reduce viral replication [13, 14, 15],
activate NK and CTL cells [16, 12, 17], and facilitate induction of immunity in uninfected target cells
[18, 19].
A number of mathematical models have looked into various aspects of HBV dynamics and that of
the immune response during infection. Ciupe et al. [20, 21] extended a standard model of immune
response to study acute HBV infection and the role of time delay associated with activation and
expansion of effector cells, and later they also looked into the role of pre-existing or vaccine-induced
antibodies in controlling the HBV infection [22]. Min et al. [23] have used a standard incidence function
rather than a mass action to account for a finite liver size and susceptibility to HBV infection, while
Gourley et al. [24] have developed a time-delayed extension of this model. Hews et al. [25] have
used a logistic growth for hepatocyte population and a standard incidence to help the model better
represent available data and achieve more realistic values for the basic reproduction number. Yousfi
et al. [26] have analysed possible mis-coordination between different branches of adaptive immune
response, more specifically, the CTLs and the antibodies, during HBV infection. In terms of the
effects of cytokines on mediating immune response, Wiah et al. [19] have studied a model that besides
the CTLs and antibodies also includes α- and β-interferons, whose role is taken to convert susceptible
hepatocytes into infection-resistant cells. Kim et al. [27] adapted an earlier model for hepatitis C
to include cytokines implicitly through allowing effector cells to cause a non-cytolytic recovery of
the infected cells, and a similar approach has also been used by other researchers [28, 29, 30] who
considered a constant rate of non-cytolytic cure alongside treatment.
In this paper we focus on the interplay between various branches of the immune system during HBV
infection, with particular emphasis on explicitly modelling the role of cytokines in mediating immune
response and controlling viral replication. In the next section we discuss the details of underlying
biological processes associated with the immune response against HBV and derive a corresponding
mathematical model. Section 3 contains analytical and numerical studies of stability of various steady
states. In Section 4 we perform numerical simulations of the model to illustrate different dynamical
regimes, as well as to investigate the effects of different types of treatment. The paper concludes with
the discussion of results and open questions.
2 Model derivation
In order to analyse various aspects of immune response to HBV infection, we build on the methodology
of some earlier HBV models [31, 32, 33]. The host liver cells are divided into populations of uninfected
cells T (t), HBV-infected cells I(t), and refractory cells R(t). Healthy hepatocytes are assumed to be
produced at a constant rate λ, die at a rate d, and they are infected by virions (free virus particles) at
a rate β. New HBV virions V (t) are produced by the infected cells at a rate p, and they are cleared
at a rate c. Interactions between all cell populations are illustrated in Fig. 1.
Adaptive immune response consists of HBsAg-specific antibodies A(t) that destroy virions at a
rate k, and HBV-specific CTLs, also referred to as effector cells, E(t). After viral clearance, because
of the long-lived plasma and memory B cells, antibody level is kept at some homeostatic level [22].
To model this, we assume that antibodies are produced at a constant rate λa, and die at per capita
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Figure 1: A diagram of immune response to HBV infection. Blue circles indicate host cells (uninfected,
infected, and refractory cells), green circles denote adaptive immune response (antibodies, CTLs),
yellow circles show cytokines (type-1 and type-2 interferon), red circle is the innate immune response
(NK cells), and grey indicates virus particles (virions).
rate da. During infection, antibodies are produced at rate q proportional to the viral load. Whilst
antibodies are responsible for eliminating free virus, CTLs instead kill infected cells at a rate µ2. Some
models assume certain basal level of CTLs s/de in the absence of infection, where s is the source of
CTLs, and 1/de is their average lifespan [20, 21]. We will instead assume the dynamics of effector
cells in the absence of infection to have the form of logistic growth with the proliferation rate re and
the carrying capacity Emax. Upon infection, the immune response is activated, and the population of
effector cells will expand at rate αIE [20, 21]. Similarly to effector cells, in the absence of infection,
NK cells are assumed to obey logistic growth with the linear growth rate rn and the carrying capacity
Nmax.
Let us now focus on the role of cytokines in the immune dynamics. Type-1 interferons IFN-α/β,
to be denoted by F1(t), are produced by infected cells [34, 12] at a rate p1, and they are destroyed at
a rate δ1. Type-2 interferons IFN-γ, denoted as F2(t), are produced by CTLs and NKs (natural killer
cells) N(t) [12, 13, 35, 36] at rates p2 and p3, respectively, and they are lost at a rate δ2. Both types of
interferons have the capacity to render the uninfected cells protected from infection through making
them resistant to infection [19, 37, 38], or by turning them into refractory cells [18, 39]. Therefore,
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the combined effect of interferons making uninfected cells refractory is taken to be ϕ1(F1 + F2) per
uninfected cell, and refractory cells can lose their viral resistance at a rate ρ [20]. During infection,
IFN-α/β are able to activate NK cells [40], while IFN-γ induces protein-10 (CXCL-10) that recruits
NK cells [41, 16] and can also activate NK cells [12]. Hence, the combined effect of interferons on
activating NK cells is taken to occur at a rate q1NF1 + q2NF2. Besides positive contribution to the
production of new NK cells, IFN-α/β also increase the cytotoxicity of NK cells and CTLs [11]. On
the other hand, IFN-γ increases the expression of MHC antigen acting to help CTLs destroy infected
cells [17], and it also enhances the activity of NK cells [42, 43]. Thus, both types of interferons
increase cytolytic activity of NKs and CTLs, and hence, we will assume that NKs and CTLs destroy
infected cells at rates µ1(1 + s1F1 + s2F2)IN and µ2(1 + s
′
1F1 + s
′
2F2)IE, respectively. Moreover,
antiviral cytokines, such as IFN-γ and TNF-α, can non-cytopathically purify viruses from infected
cells [12], so that HBV-specific CTLs and NK cells can effectively “cure” infected cells through a
non-cytolytic antiviral activity mediated by IFN-γ [12, 13, 44, 45]. Hence, infected cells can be lost
due to non-cytolytic response of IFN-γ at a rate ϕ2IF2. Studies have shown that IFN-γ can activate
a number of intracellular mechanisms that suppress viral replication [13, 14, 15, 46], while IFN-α/β
can stimulate the activation of intracellular antiviral pathways to limit the development and spread
of viral replication [12]. Thus, both types of interferons help infected cells reduce production of new
virus particles, so infected cells produce virions at a rate p/(1 + s3F1 + s4F2).
With the above assumptions, the complete model for immune response to HBV infection takes the
form
dT
dt
= λ− dT − βV T + ρR− ϕ1T (F1 + F2),
dI
dt
= βV T − δI − µ1(1 + s1F1 + s2F2)IN − µ2(1 + s′1F1 + s′2F2)IE − ϕ2IF2,
dF1
dt
= p1I − δ1F1,
dF2
dt
= p2E + p3N − δ2F2,
dN
dt
= rnN
(
1− N
Nmax
)
+ (q1F1 + q2F2)N,
dE
dt
= reE
(
1− E
Emax
)
+ αIE,
dR
dt
= ϕ1T (F1 + F2) + ϕ2IF2 − ρR,
dV
dt
=
p
1 + s3F1 + s4F2
I − cV − kAV,
dA
dt
= λa − daA− kAV + qV.
(1)
To reduce the complexity of the model and the number of free parameters, we introduce the
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following rescaled parameters
dˆ =
d
rn
, βˆ =
βλa
darn
, ρˆ =
ρλad
rnλda
, δˆ =
δ
rn
, sˆi = si
λa
da
, i = 1, 2, 3, 4,
µˆ1 =
µ1Nmax
rn
, µˆ2 =
µ2Emax
rn
, ϕˆi =
ϕiλa
darn
, pˆ1 =
p1
rn
, pˆ2 =
p2daEmax
rnλa
, pˆ3 =
p3daNmax
rnλa
,
rˆe =
re
rn
, αˆ =
αλa
rnda
, pˆ =
p
rn
, cˆ =
c
rn
, kˆ =
kλa
rnda
, dˆa =
da
rn
, qˆ =
q
rn
,
sˆ′i = s
′
i
λa
da
, δˆi =
δi
rn
, qˆi =
qiλa
rnda
, i = 1, 2,
and new variables
tˆ = rnt, T =
λ
d
Tˆ , I =
λa
da
Iˆ , F1 =
λa
da
Fˆ1, F2 =
λa
da
Fˆ2, N = NmaxNˆ , E = EmaxEˆ,
R =
λa
da
Rˆ, V =
λa
da
Vˆ , A =
λa
da
Aˆ.
Substituting these variables into the model (1) and dropping all hats gives the following non-dimensionalised
system of equations
dT
dt
= d(1− T )− βV T + ρR− ϕ1T (F1 + F2),
dI
dt
= βV T − δI − [µ1(1 + s1F1 + s2F2)N + µ2(1 + s′1F1 + s′2F2)E + ϕ2F2] I,
dF1
dt
= p1I − δ1F1,
dF2
dt
= p2E + p3N − δ2F2,
dN
dt
= N(1−N) + (q1F1 + q2F2)N,
dE
dt
= reE(1− E) + αIE,
dR
dt
= ϕ1T (F1 + F2) + ϕ2IF2 − ρR,
dV
dt
=
p
1 + s3F1 + s4F2
I − cV − kAV,
dA
dt
= da(1−A)− kAV + qV.
(2)
It is straightforward to show that this system is well-posed, i.e. its solutions with non-negative
initial conditions remain non-negative for all t ≥ 0.
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3 Steady states and their stability
We begin our analysis of the system (2) by looking at its steady states
S∗ = (T ∗, I∗, F ∗1 , F
∗
2 , N
∗, E∗, R∗, V ∗, A∗),
that can be found by equating the right-hand sides of equations in (2) to zero and solving the resulting
system of algebraic equations. Due to the high dimensionality of the system (2), it can admit a
significant number of possible steady states. Hence, in order to systematically find and analyse all of
them, we begin with steady states characterised by the absence of virus particles, i.e. V ∗ = 0, which
immediately implies I∗ = F ∗1 = 0 and T ∗ = A∗ = 1. There are four such steady states,
S∗1 = (1, 0, 0, 0, 0, 0, 0, 0, 1), S
∗
2 =
(
1, 0, 0,
p2
δ2
, 0, 1,
ϕ1p2
ρδ2
, 0, 1
)
,
S∗3 =
(
1, 0, 0,
p3
δ2 − p3q2 ,
δ2
δ2 − p3q2 , 0,
ϕ1p3
ρ(δ2 − p3q2) , 0, 1
)
,
S∗4 =
(
1, 0, 0,
p2 + p3
δ2 − p3q2 ,
δ2 − p3q2 + p2q2 + p3q2
δ2 − p3q2 , 1,
ϕ1(p2 + p3)
ρ(δ2 − p3q2) , 0, 1
)
.
Whilst the steady states S∗1 and S∗2 are feasible for any values of parameters, S∗3 and S∗4 are only
biologically feasible, provided δ2 − p3q2 > 0. Linearisation of the system (2) near each of these steady
states shows that S∗1 , S∗2 and S∗3 are always unstable, while S∗4 is stable if the following condition holds
K < Kc, K =
pβ(δ2 − p3q2)3
(c+ k)(p2s4 − p3q2 + p3s4 + δ2) , (3)
with
Kc = δp
2
3q
2
2 + µ1p
2
2q2s2 − µ1p2p3q22 + µ1p2p3q2s2 − µ2p2p3q2s′2 + µ2p23q22 − µ2p23q2s′2
−2δδ2p3q2 + δ2µ1p2q2 + δ2µ1p2s2 − δ2µ1p3q2 + δ2µ1p3s2 + δ2µ2p2s′2 − 2δ2µ2p3q2
+δ2µ2p3s
′
2 − p2p3q2ϕ2 − p23q2ϕ2 + δδ22 + δ22µ1 + δ22µ2 + δ2p2ϕ2 + δ2p3ϕ2.
(4)
When K = Kc, equilibrium S
∗
4 undergoes a steady-state bifurcation, and for K > Kc, this steady
state is unstable.
For V ∗ 6= 0, one has to distinguish between two cases, k = q and k 6= q. For k = q, one finds
A∗ = 1, and there are four associated steady states with different combinations of E∗ = 0 or E∗ 6= 0,
and N∗ = 0 or N∗ 6= 0. The first of these, S∗5 , characterised by the absence of CTLs and NKs, i.e.
E∗ = 0 and N∗ = 0, has other components given by
T ∗ =
(c+ k)(dp1s3 + δδ1)
cdp1s3 + dkp1s3 + βpδ1
, I∗ =
dδ1(pβ − cδ − kδ)
δ(cdp1s3 + dkp1s3 + βpδ1)
,
F ∗1 =
dp1(pβ − cδ − kδ)
δ(cdp1s3 + dkp1s3 + βpδ1)
, F ∗2 = 0,
R∗ =
dp1ϕ1(c+ k)(dp1s3 + δδ1)(pβ − cδ − kδ)
δρ(cdp1s3 + dkp1s3 + βpδ1)2
, V ∗ =
dδ1(pβ − cδ − kδ)
β(c+ k)(dp1s3 + δδ1)
,
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and this steady state is always unstable. The steady state S∗6 with E∗ = 0 and N∗ 6= 0 has components
given by
I∗ =
δ1F
∗
1
p1
, F ∗2 =
1 + q1F
∗
1
a
, N∗ =
δ2F
∗
2
p3
, V ∗ =
pI∗
(c+ k)(1 + s3F ∗1 + s4F ∗2 )
,
T ∗ =
d+ ϕ2I
∗F ∗2
d+ βV ∗
, R∗ =
ϕ1T
∗(F ∗1 + F ∗2 ) + ϕ2I∗F ∗2
ρ
,
where F ∗1 satisfies the cubic equation
b3(F
∗
1 )
3 + b2(F
∗
1 )
2 + b1F
∗
1 + b0 = 0,
where the coefficients b1, b2 and b3 are always positive, and
b0 = dp1
[−a3pp3β + (c+ k)(a+ s4)(a2p3δ + aδ2µ1 + ap3ϕ2 + s2δ2µ1)] , a = δ2 − p3q2
p3
.
The steady state S∗6 is also always unstable.
Similarly, the steady state S∗7 with E∗ 6= 0 and N∗ = 0 has its state variables given by
I∗ =
δ1F
∗
1
p1
, F ∗2 =
p2
δ2
(
1 +
αδ1F
∗
1
rep1
)
, E∗ =
re + αI
∗
re
, V ∗ =
pI∗
(c+ k)(1 + s3F ∗1 + s4F ∗2 )
,
T ∗ =
d+ ϕ2I
∗F ∗2
d+ βV ∗
, R∗ =
ϕ1T
∗(F ∗1 + F ∗2 ) + ϕ2I∗F ∗2
ρ
,
with F ∗1 satisfying the cubic equation
m3(F
∗
1 )
3 +m2(F
∗
1 )
2 +m1F
∗
1 + b0 = 0,
where m1, m2 and m3 are positive, and
m0 = dp
3
1r
3
e
[−βpδ22 + (c+ k)(p2s4 + δ2)(µ2p2s′2 + δδ2 + µ2δ2 + ϕ2p2)] .
This steady state is unstable for any parameter values.
The last steady state S∗8 with E∗ 6= 0 and N∗ 6= 0 has components
I∗ =
δ1F
∗
1
p1
, E∗ =
re + αI
∗
re
, F ∗2 =
αp2δ1 + rep1 [p2 + p3(1 + q)]
rep1(δ2 − p3q2) , N
∗ =
δ2F
∗
2 − p2E∗
p3
,
V ∗ =
pI∗
(c+ k)(1 + s3F ∗1 + s4F ∗2 )
, T ∗ =
d+ ϕ2I
∗F ∗2
d+ βV ∗
, R∗ =
ϕ1T
∗(F ∗1 + F ∗2 ) + ϕ2I∗F ∗2
ρ
,
and F ∗1 satisfies a cubic equation. It does not prove possible to determine stability of this steady state
in a closed form, so is has to be done numerically.
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Figure 2: Stability of the disease-free steady state S∗4 with parameter values from Table 1. Black grid
area indicates the region where there are no feasible steady states. Colour code denotes maximum
real part of the largest characteristic eigenvalue for the disease-free steady state S∗4 when it is feasible.
For k 6= q, we again have four options, depending on whether E∗ = 0 or E∗ 6= 0, and N∗ = 0
or N∗ 6= 0. Similar to the case k = q, the steady states S∗9 with E∗ = N∗ = 0, S∗10 with E∗ = 0
and N∗ 6= 0 and S∗11 with E∗ 6= 0 and N∗ = 0, are always unstable. The steady state S∗12 with all
components being positive cannot be found in a closed form.
The cases k = q and k 6= q have to be considered separately, since for k 6= q one has a relation
V ∗ = da(1−A∗)/(kA∗− q), which cannot be directly used in the case k = q with A∗ = 1. However, it
is straightforward to show that as k → q, the steady states S∗9 , S∗10, S∗11 and S∗12 converge to S∗5 , S∗6 ,
S∗7 and S∗8 , respectively. Of these steady states, only S∗4 and S∗12 (or equivalently S∗8 for k = q) can
potentially change stability, as all other steady states are unstable for any parameter values.
To gain a better understanding of how stability of different steady states is affected by various
parameters in the model, we perform numerical stability and bifurcation analysis. Baseline values of
parameters are given in Table 1 in the Appendix, though one should note that at this stage it is only
feasible to explore different qualitative scenarios, as the actual values of many of these parameters
have not yet been measured, or significant variations in their values have been reported.
Figure 2 shows regions of feasibility and stability of the disease-free steady state S∗4 . Our earlier
8
Figure 3: Stability of the endemic steady state S∗12 with parameter values from Table 1. White area
shows the region where the endemic steady state is not feasible, but the disease-free steady state S∗4
is feasible and stable. Black grid area indicates the region where there are no feasible steady states.
Colour code denotes maximum real part of the largest characteristic eigenvalue for the endemic steady
state S∗12 when it is feasible.
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Figure 4: Bifurcation diagram (a) and periods of periodic solutions (b) with parameter values from
Table 1. (a) In this figure p3 = 0.3. The blue line shows the endemic steady state, and the red line
shows the disease-free steady state, with solid (dashed) lines corresponding to stable (unstable) steady
states. At k = 6.277 and k = 10.74 there is a Hopf bifurcation of the endemic steady steady state,
and at k = 11.2389 there is a transcritical bifurcation. Between the two HB points there is a stable
periodic solution, the minimum and maximum of T are shown in green. (b) This figure shows the
dependence of the period of periodic solutions on k for p3 = 0.1 (black), p3 = 0.3 (blue), p3 = 0.5
(red).
analysis indicates that this steady state is only feasible, provided δ2−p3q2 > 0, which means that this
steady state can only exist if the rate p3 of production of IFN-γ by NK cells, and the rate q2 at which
IFN-γ in turn upregulates the production of new NK cells, are not too large, as illustrated in Fig. 2(a)
and (b). Stability of the disease-free steady state S∗4 is determined by the value of K defined in (3),
and Figs. 2(a) and (b) suggest that increasing p3 can stabilise this equilibrium if it were previously
unstable, which should be expected, as increasing the number of NK cells and the amount of IFN-γ
leads to a more effective eradication of the viral population. Similarly, increasing the rate of clearance
of virions by antibodies k, the rate at which IFN-γ inhibits production of new virus particles s4, or the
rate of IFN-γ-induced conversion from infected cells to refractory cells ϕ2, all lead to the stabilisation
of the disease-free steady state. At the same time, comparison of Fig. 2(a) with (c) and (d) indicates
that if antibodies are not very effective, i.e. if k is small, it is easier to clear the infection, i.e. achieve
stability of the disease-free steady state, by increasing production of IFN-γ by NK cells, since both s4
and ϕ2 have to be increased very significantly before the stability can be achieved.
Figure 3 illustrates how regions of feasibility and stability of the endemic steady state S∗12 depend
on system parameters. Comparison of Fig. 3(a) with Fig. 2(a) suggests that as the disease-free steady
state loses its stability, the endemic steady state becomes biologically feasible and stable. However, for
very small values of p3, there is a certain range of k values, for which the endemic steady state is also
unstable, and one could expect the appearance of periodic solutions. This is illustrated in more detail
in the bifurcation diagram shown in Fig. 4(a), which indicates that when one fixes some small value
of p3 and increases k, the endemic steady state does indeed lose its stability via a supercritical Hopf
bifurcation, and then regains it at a subcritical Hopf bifurcation for yet higher value of k. In the range
of k values where the endemic steady state S∗12 is unstable, one observes a stable periodic orbit, whose
period increases with k but reduces with p3, as shown in Fig. 4(b). The effects of varying s4 and ϕ2
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Figure 5: Stability of the endemic steady state S∗12 with parameter values from Table 1. White area
shows the region where the endemic steady state is not feasible, but the disease-free steady state S∗4
is feasible and stable. Colour code denotes maximum real part of the largest characteristic eigenvalue
for the endemic steady state S∗12 when it is feasible.
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on stability of S∗12 are similar to those of varying p3, with the exception that for small k, increasing s4
or ϕ2 does not make this steady state infeasible, i.e. biologically irrelevant. Figures 3(b) and (f) are
quite similar to each other in that for each value of k, there is some minimal value of the infection rate
β or production rate of new virions p, above which the endemic steady state S∗12 becomes biologically
feasible and stable. If k is small, then further increases of β or p do not have effect on stability, and
S∗12 remains stable, whilst for higher k increasing either β or p results in the loss of stability through
a supercritical Hopf bifurcation. A very interesting behaviour is observed in Fig. 3(d), which shows
that for k small or very large, the stability of S∗12 is unaffected by changes in the rate of production
of new antibodies q, whereas for an intermediate range of k, S∗12 is unstable for small q but gains
stability as q is increased. This is quite counter-intuitive, as one would normally expect that if more
antibodies are produced for the same viral load, this would help clear the infection. Since k is also
the rate at which antibodies are binding free virus and, hence, are removed, this means that it is the
balance between k and q that determines whether the infection is maintained at a steady level, i.e.
S∗12 is stable, or if periodic oscillations appear in the dynamics. Similar behaviour can be observed in
Fig. 3(e), which shows that the endemic steady state S∗12 is unstable for small ρ, i.e. for long periods
of viral resistance, but it stabilises as the duration of viral resistance reduces, i.e. for higher values of
ρ.
In order to better understand the role of cytokines in system’s dynamics, we present in Fig. 5
stability of the endemic steady state depending on cytokine-related parameters. Figures 5(a) and (b)
suggest that increasing the rates s1 and s2 at which IFN-α/β and IFN-γ enhance cytolytic activity of
NK cells, or the rates s3 and s4 at which these interferons inhibit production of new virions, results in
stabilisation of the endemic steady state S∗12. One should note, however, that while increasing the rates
s1 or s3, associated with IFN-α/β only acts to make the endemic steady state more stable, increasing
the rates s2 or s4 associated with IFN-γ can actually make the endemic steady state biologically
irrelevant, thus helping clear the infection by moving the system to a stable disease-free steady state.
This suggests the profoundly different effects of IFN-α/β and IFN-γ on viral dynamics. A similar
phenomenon is observed when one investigates the role of cytokines in producing refractory cells
from either uninfected or infected cells. Increasing the rate ϕ1 of conversion of uninfected cells into
refractory cells, which involves contributions from both types of interferon, results in destabilisation of
the endemic steady state. On the other hand, increasing the rate ϕ2 of non-cytolytic cure of infected
cells by IFN-γ initially stabilises the endemic steady state, but subsequent increase makes the endemic
steady state infeasible, thus leading to clearance of infection, as shown in Fig. 5(c). We have also looked
into the effects of both types of interferon on enhancing cytotoxic activity of CTLs, as represented by
parameters s′1 and s′2. In this case, numerical calculations suggest that the stability of the endemic
steady state is not sensitive to s′1, implying that this particular contribution from IFN-α/β does not
help clear the infection. In this respect, IFN-γ plays a more important role, since increasing s′2 above
a certain level makes the endemic steady state biologically irrelevant, so the system reverts to a stable
disease-free state. Finally, Figure 5(d) shows that increasing the rates q1 and q2 of cytokine-related
activation of NK cells leads to stabilisation of the endemic steady state, however, increasing the rate q2
associated with IFN-γ beyond certain level results in this steady state becoming biologically irrelevant,
thus eradicating the viral infection.
4 Numerical simulations
To demonstrate different types of dynamical behaviour that can be exhibited by the model (2) in
various parameter regimes, we solve this system numerically using the baseline values of parameters
given in Table 1 in the Appendix, and the results are shown in Figs. 6, 7, 8. In all these figures, the free
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virus V (t) exhibits the behaviour that is qualitatively similar to that of the number of infected cells,
hence, we plot instead the dynamics of the population of refractory cells R(t). Figure 6 illustrates the
dynamics of immune response when the condition (3) holds. In this case, the initial viral growth leads
to an increase in the numbers of NKs and CTLs, as well as both types of interferons, which results in
the successful clearance of the HBV infection, upon which type-1 interferons are also destroyed, and
the system settles on a stable disease-free steady state S∗4 . Figure 7 shows the dynamics in the case
where the endemic steady state S∗12 is feasible and stable. One observes that the initial viral growth
is suppressed by the combined effects of different branches of the immune system. However, the
approach to the endemic steady state is oscillatory with the amplitude of oscillations decaying, with
each subsequent viral peak being smaller than the previous one. In the case when the endemic state
is unstable due to Hopf bifurcation, one observes stable oscillations, as shown in Fig. 8. Biologically,
these would correspond to the so-called “flare-ups” [47, 48], where the infection is never completely
cleared, but through the interactions between the virus and the immune system, there are periods
of very low viral activity followed by the periods of acute viral growth. This situation is reminiscent
of the infection-induced autoimmune reaction, where initial viral infection can lead to a breakdown
of immune tolerance, so that even in the absence of any exogenous factors or subsequent infections,
patients exhibit periods of remission and relapses [49, 50]. It is worth noting that the behaviour shown
in Fig. 8 has the hallmarks of slow-fast dynamics, or relaxation oscillations, that are not uncommon in
models of immune response [51, 52]. At every “flare-up”, there is a significant growth in the number
of infected cells that triggers the proliferation of both types of interferon, as well as the growth in the
populations of CTLs and natural killer cells. All of them are growing very quickly, resulting in a fast
immune response that reduces the infection, but as the number of infected cells subsides, so do all
the various populations associated with the immune response. Hence, the infection is not completely
cleared but rather is kept in check at a very small level. Now, as the population
of susceptible cells recovers, which is happening on a much longer time-scale, more of these cells
become the target of free virus, resulting in a new episode of high viral load, and the cycle repeats.
As a next step, we look into effects of antiviral treatments on HBV. There are two main types
of drugs used to treat HBV infection: nucleot(s)ide analogues (NAs), such as lamivudine, adefovir,
entecavir, tenofovir, telbivudine, famciclovir, telbivudine, clevudine, and IFN-based therapy, which
includes stand-alone IFN-α (roferon, intron) or pegylated interferon peg-IFN-α2a/2b [28, 27, 53, 30, 1].
These treatments individually [54, 31] and in combinations [55, 29] result in either reducing the
production of new virus particles, or in blocking de novo infections. Mathematically, one can represent
these two effects by a modified viral production rate (1−)p and a modified transmission rate (1−η)β,
where 0 ≤  ≤ 1 and 0 ≤ η ≤ 1 are drug efficacies associated with inhibiting viral production and
preventing new infections, respectively. In order to characterise the overall effectiveness of treatment,
it can be helpful to consider a cumulative parameter describing the total drug effectiveness tot, which
is defined as 1− tot = (1− η)(1− ) [28]. This would allow one to determine a critical drug efficacy,
c, corresponding to stability boundary of the disease-free steady state S
∗
4 , so that this steady state
would be stable for tot > c. With these modifications, new equations for the numbers of healthy and
infected cells, as well as the free virus, have the form
dT
dt
= d(1− T )− β(1− η)V T + ρR− ϕ1T (F1 + F2),
dI
dt
= β(1− η)V T − δI − µ1(1 + s1F1 + s2F2)IN − µ2(1 + s′1F1 + s′2F2)IE − ϕ2IF2,
dV
dt
=
p(1− )
1 + s3F1 + s4F2
I − cV − kAV,
(5)
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Figure 6: Numerical solution of the model (2) with parameter values from Table 1, and p3 = 3, k = 8.
In this case, the disease-free steady state S∗4 is stable, so immune system is able to clear the initial
infection.
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Figure 7: Numerical solution of the model (2) with parameter values from Table 1, and p3 = 0.3,
k = 0.3. In this case, the system approaches a stable endemic steady state S∗12.
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Figure 8: Numerical solution of the model (2) with parameter values from Table 1, and p3 = 0.3,
k = 8. In this case, both the disease-free S∗4 and the endemic steady state S∗12 are unstable, and the
system exhibits a periodic solution.
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Figure 9: Effects of NAs and interferon therapy on the dynamics of HBV with parameter values from
Table 1, and k = 7, β = 30.(a) Stability plot for the endemic steady state S∗12, with the colour code
denoting maximum real part of the largest characteristic eigenvalue for the endemic steady state when
it is feasible. White area shows the region where the endemic steady state S∗12 is not feasible, and
the disease-free steady state S∗4 is stable. (b) Dependence of the critical drug efficacy (c) on k, with
disease being cleared for tot > c, with p3 = 0.1 (black line), p3 = 0.9 (blue line), p3 = 2 (red line).
with the rest of the equations remaining the same as in the main model (2).
Figure 9 (a) shows that for parameter values from Table 1, if η > 0.7646, then pure NAs therapy
is sufficient to destabilise the endemic steady state and thus clear the infection, and similarly, if
 > 0.7646, then just IFN-therapy can make the disease-free steady state S∗4 stable. This Figure also
suggests that disease clearance can be achieved if the combined efficacy tot exceeds some critical value
c. Figure 9 (b) illustrates how this critical combined efficacy c varies with the rate k of clearance of
free virus by antibodies and the rate p3 of production of type-2 interferons by NK cells. One observes
that the critical combined efficacy c decreases with k, implying that the faster the free virus is cleared
by antibodies, the less stringent is the requirement on the efficacy of treatment to clear the infection,
and for sufficiently high k the disease clearance can be achieved even in the absence of treatment.
Surprisingly, for the same value of k, having a higher rate of production of type-2 interferons by NK
cells requires a higher combined efficacy c for viral clearance.
Figure 10 illustrates the effect of using combined NAs and interferon therapy on chronic and
relapsing HBV infections. In both regimes, application of treatment with sub-optimal efficacy, i.e.
with tot < c, does not cause qualitative change in the system dynamics but results in an increased
number of uninfected cells and a decreased number of infected cells. On the contrary, for tot > c,
in both cases the number of infected cells is reduced to zero, and the system approaches a stable
disease-free steady state S∗4 , which corresponds to a successful clearance of infection.
5 Discussion
In this paper we have derived and analysed a new model for HBV infection with particular emphasis
on interactions between different branches of immune system, including innate immune response as
exemplified by NK cells, adaptive immune response represented by HBV-specific cytotoxic T cells
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Figure 10: Numerical solution of the model (2) with treatment (5) and parameter values from Table 1
and (k = 0.3, p = 0.3) in (a-b), and (k = 8, p = 0.3) in (c-d). In all plots, blue colour denotes a
rescaled number of uninfected cells T (t), and red colour denotes a rescaled number of infected cells
I(t). (a)-(b) Treatment of the chronic infection with tot < c (η = 0.6,  = 0.5) (a), and tot > c
(η = 0.9,  = 0.6) (b). (c)-(d) Treatment of the relapsing infection with tot < c (η = 0.2,  = 0.1)
(c), and tot > c (η = 0.2,  = 0.4) (d).
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and antibodies, and various cytokines. During infection the cytokines play an important role in
recruitment of innate and adaptive immune factors, and they also help them to be more effective, as
well as facilitate non-cytolytic cure of infected cells.
Stability analysis of the steady states has shown how various parameters affect the dynamics of
immune response, with some of the results being intuitively clear, and others being quite unexpected.
Naturally, increasing the number of NK cells, the rate of clearance of free virus by antibodies, the rate
of inhibition of viral production by IFN-γ, or the rate of conversion from infected to refractory cells,
all facilitate a more efficient clearance of infection, making the disease-free steady state stable. Once
the disease-free steady state loses its stability, the endemic equilibrium becomes biologically feasible
and stable. For sufficiently small values of the rate of production of IFN-γ by NK cells, the endemic
steady state can lose its stability via Hopf bifurcation, giving rise to stable periodic solutions. We
have found that for a very small or a very large rate of free virus clearance by antibodies, the stability
of the endemic steady state is unaffected by how quickly the new antibodies are produced, whereas
for an intermediate range of virus clearance rate, this steady state is unstable for low production of
antibodies, and gains stability as the rate of antibody production is increased. This is a very surprising
result, as normally one would expect that a higher rate of production of antibodies for the same viral
load leads to a clearance of infection, rather than stabilisation of a chronic state. The implication of
this observation is that it is not the individual rates of production of antibodies and viral clearance,
but rather the balance between them that determines whether the system maintains a chronic infection
or exhibits periodic oscillations.
In terms of the role of cytokines on mediating various branches of immune response, a surprising
result of the analysis is that increasing the rates at which IFN-α/β and IFN-γ increase cytolytic activity
of NK cells or inhibit production of free virus, actually leads to stabilisation of the endemic steady
state. The major difference in the effects of cytokines IFN-α/β and IFN-γ lies in the observation that
whilst increasing the rates associated with IFN-α/β just results in the stabilisation of an otherwise
unstable endemic steady state, increasing the same rates for IFN-γ can result in making the endemic
steady state biologically irrelevant, thus qualitatively changing the dynamics. The same result holds
for IFN-γ-facilitated non-cytolytic cure of infected cells. If the production of IFN-γ by NK cells is
too high, this makes all steady states of the system unstable, leading to persistent oscillations, thus
maintaining the infection.
We have also looked into modelling the dynamics of HBV treatment with nucleot(s)ide analogues
and/or stand-alone or pegylated interferons. Since these treatments are known to act by reducing
the appearance of new infections and blocking production of free virus, we have looked at how the
combined drug efficacy depends on these two properties. Numerical studies have shown the existence
of a minimum drug efficacy required to clear the infection, and, unexpectedly, this critical drug efficacy
is actually increasing with the rate of production of IFN-γ by NK cells.
There are several directions in which the model presented in this paper can be extended. One
important aspect of the immune dynamics is the non-instantaneous nature of several important pro-
cesses, such as the lag between infection and recruitment of CTLs, production of new virus particles
once a cell becomes infected, the time required for viral cell entry etc [56, 57]. Mathematically, this
can be represented by including discrete of distributed time delay for each of the associated processes,
which would make the model more realistic but would also make the analysis much more involved.
Furthermore, it is known that antibodies do not kill the virus particles directly, but rather stick to
them, creating a virus-antibody complex [22]. These complexes are not stable forever and can expe-
rience some dissociation, hence, explicitly including them into the model can provide better insights
into the dynamics.
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Appendix
The parameter values used for numerical simulations are given in the table below.
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Table 1: Table of baseline parameter values.
Parameter Value Definition
d 0.003 Natural death rate of uninfected cells
β 7 Infection rate
ρ 5 Rate of missing refractory state
ϕ1 14 Rate of IFN-induced conversion from uninfected cells to refractory cells
δ 0.56 Natural death rate of infected cells
µ1 5 Death rate of infected cells by NK cells
s1 1.5 Effect of IFN-α/β on NK cells to kill infected cells
s2 0.6 Effect of IFN-γ on NK cells to kill infected cells
µ2 0.14 Death rate of infected cells by HBV-specific CTLs
s′1 1.9 Effect of IFN-α/β on the HBV-specific CTLs
s′2 2 Effect of IFN-γ on the HBV-specific CTLs
ϕ2 21 Rate of IFN-γ-induced conversion from infected cells to refractory cells
p1 1 Production rate of IFN-α/β by infected cells
δ1 4.9 Natural death rate of IFN-α/β
p2 0.5 Production rate of IFN-γ by HBV-specific CTLs
p3 0.9 Production rate of IFN-γ by NK cells
δ2 5.16 Natural death rate of IFN-γ
q1 0.8 Production rate of NK cells by IFN-α/β
q2 0.6 Production rate of NK cells by IFN-γ
re 0.5 Maximal growth rate of HBV specific cytotoxic T cells
α 1 Antigen-dependent proliferation rate of HBV-specific CTLs
p 20 Production rate of free virus
s3 1.7 Effect of IFN-α/β on the production of free viruses
s4 1 Effect of IFN-γ on the production of free viruses
c 0.67 Natural clearance rate of free viruses
k 2 Clearance rate of free viruses by antibodies
da 0.332 Natural death rate of free antibodies
q 5 Production rate of free antibody by free viruses
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